This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange fell 9.56 points to 749.59 Tuesday. Jerry Solensky's shell graduate, Michigan-based veterinary drug developer Zomedica Pharmaceuticals Corp. (ZOM: $0.95), has filed a provisional application with the United States Patent and Trademark Office, for a patent for its ZM-006 drug. The drug will target a metabolic disorder in cats, dogs and horses. The application is provisional, which means it is not yet an actual patent application; it only establishes an early filing date, which could prove useful later, if there is a need to determine application priority. Now, Zomedica has one year to submit the actual application, otherwise it will need to submit a new provisional one.

The company has also filed an investigational new drug application (INDA) with the U.S. Food and Drug Administration's Center for Veterinary Medicine, for ZM-006. An INDA will allow the company to test the drug's safety and effectiveness on animals. Two months ago, Zomedica filed an INDA for another drug, ZM-012, an anti-infection drug for cats, dogs and horses. The company does not yet have a saleable product.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS